Cargando…

Letrozole in advanced breast cancer: the PO25 trial

Detalles Bibliográficos
Autor principal: Mouridsen, Henning T.
Formato: Texto
Lenguaje:English
Publicado: Springer US 2007
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2001226/
http://dx.doi.org/10.1007/s10549-007-9570-3
_version_ 1782135578618232832
author Mouridsen, Henning T.
author_facet Mouridsen, Henning T.
author_sort Mouridsen, Henning T.
collection PubMed
description
format Text
id pubmed-2001226
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-20012262007-10-09 Letrozole in advanced breast cancer: the PO25 trial Mouridsen, Henning T. Breast Cancer Res Treat Erratum Springer US 2007-05-08 2007-10 /pmc/articles/PMC2001226/ http://dx.doi.org/10.1007/s10549-007-9570-3 Text en © Springer Science+Business Media, LLC 2007
spellingShingle Erratum
Mouridsen, Henning T.
Letrozole in advanced breast cancer: the PO25 trial
title Letrozole in advanced breast cancer: the PO25 trial
title_full Letrozole in advanced breast cancer: the PO25 trial
title_fullStr Letrozole in advanced breast cancer: the PO25 trial
title_full_unstemmed Letrozole in advanced breast cancer: the PO25 trial
title_short Letrozole in advanced breast cancer: the PO25 trial
title_sort letrozole in advanced breast cancer: the po25 trial
topic Erratum
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2001226/
http://dx.doi.org/10.1007/s10549-007-9570-3
work_keys_str_mv AT mouridsenhenningt letrozoleinadvancedbreastcancerthepo25trial